docetaxel anhydrous has been researched along with phosphotyrosine in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (phosphotyrosine) | Trials (phosphotyrosine) | Recent Studies (post-2010) (phosphotyrosine) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 6,475 | 4 | 751 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gooding, WE; Grandis, JR; Li, M; Lui, VW; Niwa, H; Wentzel, AL | 1 |
1 other study(ies) available for docetaxel anhydrous and phosphotyrosine
| Article | Year |
|---|---|
Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Coloring Agents; DNA-Binding Proteins; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotides, Antisense; Phosphotyrosine; Signal Transduction; STAT3 Transcription Factor; Taxoids; Tetrazolium Salts; Thiazoles; Time Factors; Trans-Activators; Vascular Endothelial Growth Factor A | 2003 |